Why the study?
Improved cancer survival is accompanied by high rates of CV toxicities across diverse cancer drugs, creating complex long-term care needs that require multidisciplinary cardio-oncology strategies.
This document provides an overview of cardio-oncology strategies for risk assessment, prevention, and management of cancer therapy-related cardiotoxicities, highlighting the need for multidisciplinary collaboration and future research.
No takes yet. Share an insight, caveat, or question.
Supports multidisciplinary cardio-oncology care; leaves open prospective validation of risk assessment and prevention strategies.
Zamorano et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: